Volume 6, Issue 1, March 2018, Page: 1-7
IDH1 Mutation in Gliomas in Baghdad by Immunohistochemical Study
Zahraa Marwan Shaban, Pathology Department and Forensic Medicine, College of Medicine, University of Mosul, Mosul, Iraq
Salim Rasheed Al-Aubaidy, Pathology Department and Forensic Medicine, College of Medicine, University of Baghdad, Baghdad, Iraq
Ameer Dhahir Hameedi, Pathology Department and Forensic Medicine, College of Medicine, University of Baghdad, Baghdad, Iraq
Received: Nov. 7, 2017;       Accepted: Nov. 20, 2017;       Published: Jan. 11, 2018
DOI: 10.11648/j.ijgg.20180601.11      View  1666      Downloads  114
Abstract
IDH1 (isocitrate dehydrogenase 1) mutation might be encounter in the low-grade glioma occurs in early stages of development and directs the progression of the tumor to a higher grade. Aim of the study was to assess the frequency of IDH1 mutation in Iraqi patients with gliomas by immunohistochemical study, to correlate its immunoreactivity with some clinicopathological parameters. The study did on formalin fixed, paraffin embedded tumor tissue from 66 patients with different grades of intracranial gliomas of both gender and all age groups in the Baghdad city were collected in this retrospective and prospective randomized study. Ten normal brain tissue samples in form of paraffin blocks took from forensic medicine unit. New technique used, which is manual tissue microarray Immunohistochemical detection of IDH1 antibodies did by Dako autostainer link 48. Positive cytoplasmic IDH1 staining was found in 38 (57.6%) of cases of glioma. In adult gliomas, secondary glioblastoma multiforme, low grade astrocytoma and oligodendroglial tumors had the greatest values of IDH1 positivity (87%, 80% and 72.72% respectively) followed by anaplastic astrocytoma (42%), then primary glioblastoma multiforme (26%). Males and females expressed the IDH1 equally. The conclusions from the work were IDH1 mutation commonly existed in adult gliomas, low-grade gliomas and secondary glioblastoma, it had no role in pediatric gliomas, and it could be a diagnostic and prognostic marker.
Keywords
IDH1, Adults, Pediatric, Manual Tissue Microarray, Glioma, Immunohistochemical Study
To cite this article
Zahraa Marwan Shaban, Salim Rasheed Al-Aubaidy, Ameer Dhahir Hameedi, IDH1 Mutation in Gliomas in Baghdad by Immunohistochemical Study, International Journal of Genetics and Genomics. Vol. 6, No. 1, 2018, pp. 1-7. doi: 10.11648/j.ijgg.20180601.11
Copyright
Copyright © 2018 Authors retain the copyright of this article.
This article is an open access article distributed under the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Reference
[1]
Schwartzbaum JA, Fisher JL, Aldape KD, Wrensch M. Epidemiology and molecular pathology of glioma. Nature Clinical Practice Neurology. 2006; 2 (9): 494-503.
[2]
Ostrom QT, Bauchet L, Davis FG, Deltour I, Fisher JL, Langer ChE, et al. The epidemiology of glioma in adults: a “state of the science” review. Neuro-Oncology. 2014; 16 (7): 896–913.
[3]
Kumar V, Abbas AK, Aster J. Central Nervous System. In: Robbin's basic pathology, 9th edition. Elsevier/ Philadelphia, 2013; p842.
[4]
Louis DN, Perry A, Reifenberger G, Deimling AV, Figarella‑Branger D, Cavenee WK, et al. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol. 2016; 131: 803–820.
[5]
Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, et al. The 2007 WHO Classi Wcation of Tumours of the Central Nervous System. Acta Neuropathol. 2007; 114: 97–109.
[6]
Nikiforova MN, Hamilton RL. Molecular Diagnostics of Gliomas. Arch Pathol Lab Med. 2011; 135: 558–568.
[7]
Xia L, Wu B, Fu Z, Feng F, Qiao E, Li Q, et al. Prognostic role of IDH mutations in gliomas: a meta-analysis of 55 observational studies. Oncotarget 2015; 6 (19): 17354-17365.
[8]
Jansen M, Yip S, Louis DN. Molecular pathology in adult neuro-oncology: an update on diagnostic, prognostic and predictive markers. Lancet Neurol. 2010; 9 (7): 717–726.
[9]
Balss J, Meyer J, Mueller W, Korshunov A, Hartmann C, and Von Deimling A. Analysis of the IDH1 codon 132 mutation in brain tumor. Act Neuropathol. 2008; 116: 597-602.
[10]
Ellison D, Love S, Chimelli L, et al. Astrocytic neoplasms. In: Neuropathology, A reference text of CNS pathology, third edition. Elsevier Inc., Italy, 2013; pp 705-28.
[11]
Thon N, Eigenbrod S, Grasbon-Frodl EM, et al. Novel molecular stereotactic biopsy procedures reveal intratumoral homogeneity of loss of heterozygosity of 1p/19q and TP53 mutations in World Health Organization grade II gliomas. J Neuropathol Exp Neurol. 2009; 68 (11): 1219–1228.
[12]
https://www.ncbi.nlm.nih.gov/gene?term=3417 Last update: 16-Jul-2017 Last accessed 70/7/2017.
[13]
Lee SM, Koh HJ, Park DC, et al. Cytosolic NADP(+)-dependent isocitrate dehydrogenase status modulates oxidative damage to cells. Free Radic Biol Med. 2002; 32 (11): 1185–96.
[14]
Cohen A, Holmen Sh, Colman H. IDH1 and IDH2 Mutations in Gliomas. Curr Neurol Neurosci Rep. 2013; 13 (5): 345.
[15]
Kloosterhof NK, Bralten LB, Dubbink HJ, French PJ, van den Bent MJ. Isocitrate dehydrogenase-1 mutations: a fundamentally new understanding of diffuse glioma? Lancet Oncol. 2011; 12 (1): 83–91.
[16]
Sonoda Y, Kumabe T, Nakamura T, Saito R, Kanamori M, Yamashita Y, et al. Analysis of IDH1 and IDH2 mutations in Japanese glioma patients. Cancer Science. 2009; 100: 1996-1998.
[17]
Pollard PJ, Ratcliffe PJ. Cancer. Puzzling patterns of predisposition. Science. 2009; 324 (5924): 192–4.
[18]
Capper D, WeiBert S, Balss J, Habel A, Meyer J, Jaer D, et al. Characterization of R132H Mutation-specific IDH1 Antibody Binding in Brain Tumors. Brain Pathol. 2010; 20; 245-254.
[19]
Guo Ch, Pirozzi ChJ, Lopez GY, Yan H. Isocitrate dehydrogenase mutations in gliomas: mechanisms, biomarkers and therapeutic target. Curr Opin Neurol. 2011 December; 24 (6): 648–652.
[20]
Watanabe T, Nobusawa S, Kleihues P, and Ohgaki H. IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas. Am J Pathol. 2009; 174: 1149-1153.
[21]
Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, Yuan W, et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med. 2009; 360: 765–773.
[22]
Kang MR, Kim MS, Oh JE, et al. Mutational analysis of IDH1 codon 132 in glioblastomas and other common cancers. Int J Cancer 2009; 125: 353–5.
[23]
Yan H, Bigner DD, Velculescu V, Parsons DW. Mutant Metabolic Enzymes Are at the Origin of Gliomas. Cancer Res 2009; 69 (24): 9157–9.
[24]
Parsons DW, Jones S, Zhang X, et al. An integrated genomic analysis of human glioblastoma multiforme. Science. 2008; 321 (5897): 1807–1812.
[25]
Van den JM, Dubbink HJ, Marie Y, Brandes AA, Taphoorn MJB, Wesseling P, et al. IDH1 and IDH2 Mutations Are Prognostic but not Predictive for Outcome in Anaplastic Oligodendroglial Tumors: A Report of the European Organization for Research and Treatment of Cancer Brain Tumor Group. Clin Cancer Res 2010; 16 (5): 1597–604.
[26]
Hartmann C, Meyer J, Balss J, et al. Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1010 diffuse gliomas. Acta Neuropathol. 2009; 118: 469–474.
[27]
http://www.3dhistech.com/TMA.
[28]
http://www.agilent.com/en/products/immunohistochemistry/
[29]
Saeed MS. IDH1 Mutation in Gliomas in Mosul City - Iraq. OA Maced J Med Sci. 2015 Jun 15; 3 (2): 250-255.
[30]
Sanson M, Marie Y, Paris S, Idbaih A, Laffaire J, Ducrary F, et al. Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas. J Clin Oncol. 2009; 27: 4150–4154.
[31]
Ichimura K, Pearson DM, Kocialkowski S, Bucklund LM, Chan R, Jones DTW, et al. IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas. Neuro-Oncology 2009; 11: 341–347.
[32]
Daniel J. et al. Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas The Cancer Genome Atlas Research Network. N Engl J Med 2015; 372: 2481-98.
[33]
Takano S, Kato Y, Yamamoto T, Kaneko MK, Ishikawa E, Tsujimoto Y, et al. Immunohistochemical detection of IDH1 mutation, p53, and internexin as prognostic factors of glial tumors. J Neurooncol. 2012; 108 (3): 361-373.
[34]
Karsy M, Guan J, Cohen AL, Jensen RL, Colman H. New Molecular Considerations for Glioma: IDH, ATRX, BRAF, TERT, H3 K27M. Current Neurology and Neuroscience Reports 2017; 17: 19.
[35]
Labussiere M, Marc SM, Idbaih A and Delattre JY. IDH1 Gene Mutations: A New Paradigm in Glioma Prognosis and Therapy? The Oncologist. 2010; 15; 196-199.
[36]
Leibetseder A, Ackerl MM, Flechl B, Wöhrer A, Widhalm G, Dieckmann K. Outcome and molecular characteristics of adolescent and young adult patients with newly diagnosed primary glioblastoma: a study of the Society of Austrian Neurooncology (SANO). Neuro Oncol. 2013; 15 (1): 112-121.
[37]
Dimitrov L, Hong ChS, Yang Ch, Zhuang Z, Heiss JD. New Developments in the Pathogenesis and Therapeutic Targeting of the IDH1 Mutation in Glioma. Int. J. Med. Sci. 2015; 12 (3): 201-213.
[38]
Toedt G, Barbus S, Wolter M, Felsberg J, Tews B, Blond F, et al. Molecular signatures classify astrocytic gliomas by IDH1 mutation status. Int J Cancer. 2011; 128: 1095–1103.
[39]
Jha P, Suri V, Sharma V, Singh G, Sharma MC, Pathak p et al. IDH1 mutations in gliomas: First series from a tertiary care centre in India with comprehensive review of literature. Exper Mol Pathol. 2011; 91: 385–393.
[40]
Nobusawa S, Watanabe T, Kleihus P, et al. IDH1 mutation as molecular signature and predictive factor of secondary glioblastomas. Clin Cancer Res. 2009; 15: 6002-6007.
[41]
Hartmann C, Meyer J, Balss J, et al. Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1010 diffuse gliomas. Acta Neuropathol. 2009; 118: 469–474.
[42]
Rivera-Zengotita M, and Yachnis AT. Gliosis versus glioma? Don’t grade until you know. Adv Anat Pathol. 2012; 19 (4): 239-249.
[43]
Camelo-Piragua S, Jansen M, Ganguly A, Kim JC, Louis DN, and Nutt CL. Mutant IDH1-specific immunohisochemistry distinguishes diffuse astrocytoma from astrocytosis. Act Neuropathol. 2010; 119: 509-511.
[44]
Ohgaki H, and Kleihues P, Genetic profile of astrocytic and oligodendroglial gliomas. Brain Tumor Pathol. 2011; 28 (3): 177-183.
[45]
Capper D, Sahm F, Hartmann C, Meyermann R, von Deimling A, Schittenhelm J. Application of mutant IDH1 antibody to differentiate diffuse glioma from nonneoplastic central nervous system lesions and therapy-induced changes. Am J Surg Pathol. 2010; 34 (8): 1199–1204.
[46]
Horbinski C, Kofler J, Kelly LM, Murdoch GH, Nikiforova MN. Diagnostic use of IDH1/2 mutation analysis in routine clinical testing of formalin-fixed, paraffin-embedded glioma tissues. J Neuropathol Exp Neurol. 2009; 68 (12): 1319–1325.
[47]
Pollack IF, Hamilton RL, Sobol RW, Nikiforova MN, Lyons-Weiler MA, La Framboise WA et al. IDH1 mutations are common in malignant gliomas arising in adolescent: a report from the Children’s Oncology Group. Childs Nerv Syst. 2011; 27 (1): 87-94.
[48]
Antonelli M, Buttarelli FR, Arcella A, et al. Prognostic significance of histological grading, p53 status, YKL-40 expression, and IDH1 mutations in pediatric high-grade gliomas. J Neurooncol. 2010 Sep; 99 (2): 209-15.
[49]
Korshunov A, Meyer J, Capper D, Christians A, Remke M, Witt H, et al. Combined molecular analysis of BRAF and IDH1 distinguishes pilocytic astrocytoma from diffuse astrocytoma. Acta Neuropathol. 2009; 118: 401–405.
[50]
Paugh BS, Qu C, Jones C, Liu Z, Adamowicz-Brice M, Zhang J, et al. Integrated molecular genetic profiling of pediatric high-grade gliomas reveals key differences with the adult disease. J Clin Oncol. 2010; 28: 3061-3068.
[51]
R. Stupp, M. Brada, M. J. van den Bent, J.-C. Tonn & G. Pentheroudakis. High-grade glioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology 2014; 25 (3): iii93–iii101.
[52]
Tareq A. Juratli TA, Kirsch M, Robel K, Soucek S, Geiger K, et al. IDH mutations as an early and consistent marker in low-grade astrocytomas WHO grade II and their consecutive secondary high-grade gliomas. J Neurooncol 2012; 108: 403–410.
[53]
Beiko J, Suki D, Hess KR, Fox BD, Cheung V, Cabral M, et al. IDH1 mutant malignant astrocytomas are more amenable to surgical resection and have a survival benefit associated with maximal surgical resection. Neuro-oncology 2014; 16: 81-91.
[54]
SongTao Q, Lei Y, Si G, YanQing D, HuiXia H, XueLin Z, et al. IDH mutations predict longer survival and response to temozolomide in secondary glioblastoma. Cancer science. 2012; 103: 269-73.
Browse journals by subject